-transparent.png){kind=logo}
Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4'-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4'-deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.
Related Publications
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
September 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
January 1983,
Investigational new drugs,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
May 1991,
Investigational new drugs,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
August 1990,
Investigational new drugs,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
April 1989,
Clinical pharmacology and therapeutics,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
January 1986,
Investigational new drugs,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
June 1990,
American journal of clinical oncology,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
January 1985,
Investigational new drugs,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
February 1991,
Investigational new drugs,
T Braich, and
F R Ahmann, and
H S Garewal, and
A Robertone, and
S E Salmon
February 1990,
Investigational new drugs,
